In an exploratory trial for Alzheimer's disease, LM11A-31 meets the primary end point.

Published Date: 23 May 2024

Treatment with LM11A-31 not only proved safe and tolerable, but it also significantly altered Aß40 and Aß42, with no discernible change in the ratio of Aß42 to Aß40.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Positive Survival Data in Lung Cancer With Perioperative Therapy

2.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

3.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

4.

For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.

5.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot